Letrozole

About

Therapy type: Hormone therapy

Therapy strategy: Aromatase inhibition

Mappings

NCI Thesaurus: Letrozole (coding:ncit:C1527)

RxNorm: letrozole (coding:rxcui:72965, coding:omop:4297547)

SNOMED: Letrozole (coding:sctid:386911004, coding:omop:1315946)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations Biomarkers Cancer types Therapies
FDA (2) ER positive, HER2-negative Invasive Breast Carcinoma Abemaciclib, Letrozole
FDA (2) HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
FDA (2) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Abemaciclib, Letrozole
FDA (1) ER positive, HER2-positive Invasive Breast Carcinoma Lapatinib, Letrozole
FDA (1) HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
FDA (1) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
FDA (1) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Palbociclib
FDA (1) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib
FDA (1) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Palbociclib
FDA (1) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Letrozole, Ribociclib
FDA (1) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib
FDA (1) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Letrozole, Ribociclib
FDA (1) HC (1) ER positive, HER2-negative Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
FDA (1) HC (1) HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib
FDA (1) HC (1) ER positive, HER2-negative, PR positive Invasive Breast Carcinoma Goserelin, Letrozole, Ribociclib